Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (14)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Cavill, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cavill, I.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrol Dial Transplant (2003) 18: VIII24-VIII28
© 2003 European Renal Association-European Dialysis and Transplant Association

Intravenous iron as adjuvant therapy: a two-edged sword?

Ivor Cavill

Department of Haematology, University of Wales College of Medicine, Cardiff, UK

Correspondence and offprint requests to: Ivor Cavill, Department of Haematology, University of Wales College of Medicine, Heath Park, Cardiff CF14 4XU, UK. Email: icavill{at}ukanaemia.co.uk

Abstract

The importance of iron in the manufacture of erythrocytes is self-evident. In recent years, the treatment of anaemia of end-stage renal disease with recombinant human erythropoietin (epoetin) has been optimized by adequate iron supply. Intravenous therapy with dextran-free iron compounds has become the ideal and necessary companion of epoetin therapy. Anxiety has been expressed by clinicians and researchers over the impact of excess levels of iron following i.v. administration. Their concerns have included the potential for short-term side effects such as anaphylactic reactions and response to ‘free iron’. Long-term concerns have included the possibility of increased infection, oxidative stress and cardiovascular disease with higher levels of iron. The literature also implies that i.v. iron could be a ‘two-edged sword’, i.e. on the one hand, it optimizes epoetin therapy, while on the other, it puts the patient at greater risk of other complications. This review assesses the evidence for these concerns and concludes that i.v. therapy with dextran-free iron compounds, such as iron sucrose, optimizes epoetin therapy with no direct evidence of any short-term or long-term complications.

Keywords: iron; adjuvant therapy; epoetin; side effects; iron sucrose; anaphylaxis


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Nephrol Dial TransplantHome page
L. Schaefer and R. M. Schaefer
A primer on iron therapy
Nephrol. Dial. Transplant., September 1, 2007; 22(9): 2429 - 2431.
[Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
L. Maynor and D. F Brophy
Risk of Infection with Intravenous Iron Therapy
Ann. Pharmacother., September 1, 2007; 41(9): 1476 - 1480.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
W. H. Horl
Clinical Aspects of Iron Use in the Anemia of Kidney Disease
J. Am. Soc. Nephrol., February 1, 2007; 18(2): 382 - 393.
[Full Text] [PDF]

Home page
 CirculationHome page
Y.-D. Tang and S. D. Katz
Anemia in Chronic Heart Failure: Prevalence, Etiology, Clinical Correlates, and Treatment Options
Circulation, May 23, 2006; 113(20): 2454 - 2461.
[Full Text] [PDF]

Home page
 CirculationHome page
D. L. van der A, J. J.M. Marx, D. E. Grobbee, M. H. Kamphuis, N. A. Georgiou, J. H. van Kats-Renaud, W. Breuer, Z. I. Cabantchik, M. Roest, H. A.M. Voorbij, et al.
Non-Transferrin-Bound Iron and Risk of Coronary Heart Disease in Postmenopausal Women
Circulation, April 25, 2006; 113(16): 1942 - 1949.
[Abstract] [Full Text] [PDF]

Home page
 DTBHome page
Epoetins and {blacktriangledown}darbepoetin alfa in malignant disease
DTB, March 1, 2004; 42(3): 21 - 24.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.